BrianRLaneMD
Urology • Grand Rapids, MIProfessor at Michigan State University College of Human Medicine and Urologic Oncology Research Director at Corewell Health West
Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1900 Wealthy St SE Ste 100
Grand Rapids, MI 49506Phone+1 616-267-7333
Summary
- Brian Lane, MD is a urologist based in Grand Rapids, MI specializing in urologic oncology and minimally invasive urologic surgery. He completed his residency in Urology at the Cleveland Clinic Foundation and is an alum of the University of Michigan Medical School. Dr. Lane has conducted clinical trials including "TAP Versus Thoracic Epidural in Major Abdominal Resections" and "TXA Study in Major Oncologic Surgery." He is recognized for his academic contributions having published various papers in reputable medical journals such as BJU International and Nature Reviews Urology. Dr. Lane was awarded the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012 and is a fellow of the American College of Surgeons.
Education & Training
Cleveland Clinic FoundationResidency, Urology, 2002 - 2008
University of Michigan Medical SchoolClass of 2002
Certifications & Licensure
MI State Medical License 2009 - 2025
OH State Medical License 2002 - 2022
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- TXA Study in Major Oncologic Surgery Start of enrollment: 2012 Jun 12
- TAP Versus Thoracic Epidural in Major Abdominal Resections Start of enrollment: 2013 Dec 03
Publications & Presentations
PubMed
- The use of nephron-sparing intervention does not appear to be compromised after a period of active surveillance for patients with cT1 renal masses.Michael Wang, Aaron Wilke, Samuel Goorman, Andrew McElroy, Jack Vercnocke
Urologic Oncology. 2025-04-01 - 1 citationsImpact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.Todd M Morgan, Stephanie Daignault-Newton, Daniel E Spratt, Rodney L Dunn, Udit Singhal
European Urology. 2025-02-01 - Concordance of surgical treatment selection with the AUA guidelines for localized renal masses.Bassel R Salka, Dennis Boynton, Chibuzor Nwachukwu, Bruce Lyu, Sabrina L Noyes
Urologic Oncology. 2025-01-29
Journal Articles
- Assessment of Volume Preservation Performed Before or After Partial Nephrectomy Accurately Predicts Postoperative Renal Function: Results from a Prospective Multicente...Alexander Kutikov, Robert G Uzzo, Brian R Lane, Urologic Oncology
- Functional Duration of Closure Systems Used in Partial NephrectomyBrian Lane, MD, The Journal of Urology
Press Mentions
In and Out Surgeries Become the Norm During PandemicOctober 29th, 2021
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerNovember 21st, 2019
PCa Grade Group Better Predicts Pathologic Outcomes, RecurrenceFebruary 14th, 2019- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
